Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® HCV / Hepatitis specialty page provides HCV / hepatitis-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


Four New Year's Resolutions for ID Specialists: Public Health Watch
Herewith, 4 New Year’s resolutions for the infectious disease community—at least according to us here on the Public Health Watch.
Electronic Health Record Prompt Improves HCV Screenings
The results of a new study show that when a best practice advisory (BPA) displayed in the electronic health record of patients in the baby boomer generation, it prompted a 5-fold increase in screening for hepatitis C virus (HCV) in this population.
Relaxed Medicaid Regulations Are Giving More Individuals Access to Hepatitis C Treatment
Hepatitis C is more curable than ever thanks to direct-acting antivirals, and now, a new study shows how expanded access to these drugs through Medicaid is helping more individuals get treated.
HCV Cure Rates in Co-Infected Patients Can Be as High as HCV Mono-Infected Patients
The results of a new study show that patients who are co-infected with the hepatitis C virus (HCV) and HIV can experience cure rates similar to individuals infected with HCV alone when both groups receive direct-acting antiviral drugs.
HEPLISAV-B Approved by FDA
The vaccine is the only 2-dose regimen for the prevention of infection by all known subtypes of hepatitis b in adults 18 and older.
Treating HCV in HIV-Coinfection: Still a Therapeutic Dilemma?
Despite the availability of highly active agents against HCV, HIV-infected patients require special considerations for drug interactions when considering treatment options.  
The Challenge of Eliminating Hepatitis C Virus in the United States
The ambitious goal of global elimination of the virus by 2030 will take buy-in from all major stakeholders, including the United States.
ID Week 2017 Closing Plenary Provides Guarded Optimism for Coming Decades
Thoughts leaders believe infectious disease treatment is in the middle of a sea change, moving from antibiotics to antibodies.